A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition
出版年份 2020 全文链接
标题
A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition
作者
关键词
FAK, Ibrutinib, EGFR, ESCC, Combination therapy
出版物
BIOCHEMICAL PHARMACOLOGY
Volume 183, Issue -, Pages 114318
出版商
Elsevier BV
发表日期
2020-11-05
DOI
10.1016/j.bcp.2020.114318
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
- (2019) Rui-Mei Feng et al. Cancer Communications
- An ADAM12 and FAK positive feedback loop amplifies the interaction signal of tumor cells with extracellular matrix to promote esophageal cancer metastasis
- (2018) Man-Li Luo et al. CANCER LETTERS
- Epidemiology of Esophageal Squamous Cell Carcinoma
- (2018) Christian C. Abnet et al. GASTROENTEROLOGY
- Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
- (2018) Jing Hu et al. MOLECULAR CANCER THERAPEUTICS
- FAK inhibitors in Cancer, a patent review
- (2017) Peng-Cheng Lv et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
- (2017) Irene Yushing Chong et al. GUT
- Oesophageal cancer
- (2017) Elizabeth C. Smyth et al. Nature Reviews Disease Primers
- Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China
- (2017) Liang He et al. Cancer Biology & Medicine
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular Pathways: Endothelial Cell FAK--A Target for Cancer Treatment
- (2016) M. Roy-Luzarraga et al. CLINICAL CANCER RESEARCH
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
- (2015) Dongxian Jiang et al. BMC CANCER
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
- (2015) A. J. Gunderson et al. Cancer Discovery
- Incidence trend of esophageal squamous cell carcinoma: an analysis of Surveillance Epidemiology, and End Results (SEER) database
- (2014) Smith Giri et al. CANCER CAUSES & CONTROL
- EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer
- (2014) Christiane Daniela Fichter et al. INTERNATIONAL JOURNAL OF CANCER
- Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
- (2014) Nicole Grabinski et al. INVESTIGATIONAL NEW DRUGS
- Understanding the Roles of FAK in Cancer
- (2014) Hyunho Yoon et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Nuclear FAK: a new mode of gene regulation from cellular adhesions
- (2013) Ssang-Taek Steve Lim MOLECULES AND CELLS
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis
- (2010) Xiaofeng Zhao et al. ADVANCED DRUG DELIVERY REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started